Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medic
Seeking approval for mutant BRCA patients treated with two or more
FDA Grants Priority Review Status
Assigns PDUFA Date of February 23, 2017
BOULDER, Colo.--(BUSINESS WIRE)--Aug. 23, 2016--
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food
and Drug Administration (FDA) has accepted Clovis’ New Drug Application
(NDA) for accelerated approval of rucaparib and gra...
Rucaparib NDA submission completed in late June for treatment of
patients with advanced ovarian cancer with deleterious BRCA mutated
FDA decision on filing and determination of PDUFA date is
anticipated in late August
Rucaparib MAA submission on track for Q4 2016
Rucaparib NDA dataset accepted for an oral presentation at ESMO
2016 Congress in October
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 26, 2016--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter
2016 financial results on Monday, August 8, 2016, after the close of the
U.S. financial markets. Clovis’ senior management will host a conference
call and live audio webcast at 4:30 p.m. ET that day to discuss the
company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.